New Drugs and Routine Screenings to Drive Global Prostrate Cancer Therapeutics Market

Several studies have shown that prostate cancer is one of the biggest health hazards amongst men and its threat has been growing at an alarming pace. It is a type of cancer that affects men and is the sixth most common type of cancer seen in less developed nations. Prostate cancer is known to grow far more aggressively in younger men than in older men. However, the increasing number of screenings, early diagnosis, and advent of better therapeutics is increasing the chances of survival for prostate cancer patients. Though the cause of prostate cancer remains largely unknown, medical practitioners associate obesity and history of cancer in the family with its occurrence. Furthermore, a person suffering from cardiovascular diseases is far more susceptible to advanced metastatic cancer.

Get sample report copy or for further inquiries http://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=6562

Johnson & Johnson Acquires Aragon Pharmaceuticals to Tackle Slowdown
 
Demand for drugs such as Zytiga by Johnson & Johnson, Xtandi by Astellas Pharma Inc. or Medivation, Inc., Provenge by Dendreon Corporation, Jevtana by Sanofi, and Xofigo by Bayer Healthcare Pharmaceutical, Inc. is driving the global prostate cancer therapeutics market. In 2013, Johnson & Johnson acquired Aragon Pharmaceuticals. This move proved to be very important not just for the company, but for the industry on the whole. With this acquisition, Johnson & Johnson became the owner of the ARN-509 drug that treats castration-resistant prostate cancer. This drug is a second-generation androgen receptor signaling inhibitor and is expected to earn Johnson & Johnson revenue equivalent to before the sales of Zytiga slowed down. 
 
Xtandi Creates a Tough Challenge for Zytiga
 
Zytiga hit the market in 2011 and recorded sales worth US$1 billion in 2012. This drug has been designed to target the CYP17A1 enzyme, which is largely responsible for production of androgen. However, as Zytiga inches closer to losing its patent protection in 2016, Johnson & Johnson is facing tough competition from products such as Xtandi made by Astellas Pharma, Inc./Medivation, Inc. Xtandi’s sales have already matched Zytiga’s record.
 
The major restraint on the global prostate cancer therapeutics market is the exceptionally high price of some of the latest drugs. This restraint gets even more complicated when patients are unsure about reimbursement policies. Despite these odds, the global prostate cancer therapeutics market will surge as the awareness about this type of cancer increases, the scale of urbanization expands, and governments across the globe look at funding cancer treatments to save lives. 
 
North America to Dominate Global Prostate Cancer Therapeutics Market
 
Geographically, the global prostate cancer therapeutics market is segmented into Europe, Asia Pacific, North America, and Rest of the World. According to a report recently published by Transparency Market Research, the highest number of prostate cancer cases are reported in America, followed by Europe. Estimates suggest that in 2014 alone, over 230,000 new cases of prostate cancer were reported in the U.S. On the other hand, the count in U.K. came to about 40,000 new cases, out of which 11,000 proved fatal. Looking at these figures, analysts have affirmed that the prostate cancer therapeutics market has a strong foothold in North America, while Asia remains the smallest regional contender.
 
Some of the key players in the prostate cancer therapeutics market are Johnson & Johnson, Astellas Pharma, Inc., AstraZeneca plc, Sanofi, Ipsen SA, Medivation, Inc., and Bayer Healthcare Pharmaceutical, Inc.
 
Browse Full Global Prostrate Cancer Therapeutics Market Research Report With Complete TOC @ http://www.transparencymarketresearch.com/prostate-cancer-therapeutics-market.html

About Us: 

Transparency Market Research (TMR) is a U.S. based provider of syndicated research, customized research, and consulting services. TMR’s global and regional market intelligence coverage includes industries such as pharmaceutical, chemicals and materials, technology and media, food and beverages, and consumer goods, among others. Each TMR research report provides clients with a 360-degree view of the market with statistical forecasts, competitive landscape, detailed segmentation, key trends, and strategic recommendations.

Contact:

Mr. Nachiket Ghumare
90 State Street, Suite 700
Albany, NY 12207
United States.
Tel: +1-518-618-1030
USA - Canada Toll Free: 866-552-3453
Email: sales@transparencymarketresearch.com
Website: http://www.transparencymarketresearch.com